Anti-PD-1 Antibody Camrelizumab Combined With Albumin-bound Paclitaxel for Recurrent and Persistent Advanced Cervical Cancer Refractory to Platinum-based Chemotherapy: A Single Arm, Single Center, Open, Phase II Trial
Latest Information Update: 17 Mar 2022
At a glance
- Drugs Camrelizumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 12 Mar 2022 Status changed from recruiting to completed.
- 10 Dec 2019 New trial record
- 05 Dec 2019 Planned End Date changed from 11 Jun 2021 to 6 Jun 2021.